D-0474-2017 Class II Terminated

Recalled by Aurobindo Pharma USA Inc — Plainsboro, NJ

FDA drug recall D-0474-2017 was initiated by Aurobindo Pharma USA Inc on Dec 22, 2016 and is designated Class II. Reason for recall: Failed Tablet/Capsule Specifications: Some bottles contain punctured, and/or clumped/melted capsules. The recall status is terminated (terminated Mar 19, 2019). Affected quantity: 47,040 bottles.

Recall details

Product Type
Drugs
Report Date
Feb 22, 2017
Initiation Date
Dec 22, 2016
Termination Date
Mar 19, 2019
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
47,040 bottles

Product description

Venlafaxine Hydrochloride extended release capsules, 37.5 mg, 30-count bottles, Rx Only, Manufactured for: Aurobindo Pharma USA, Inc. 2400 Route 130 North, Dayton, NJ 08810 Manufactured by: Aurobindo Pharma Limited Hyderabad-500 072 India, NDC 65862-527-30

Reason for recall

Failed Tablet/Capsule Specifications: Some bottles contain punctured, and/or clumped/melted capsules.

Distribution pattern

Nationwide in the US

Code information

Lot #: VI3716010-A, Exp. 04/2018

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0474-2017
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0474-2017. Report a data issue: hello@regdatalab.com.